Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 9, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-05
DOI
10.1038/s41419-018-0943-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MIR-646 Regulates Cell Proliferation, Migration and Invasion by Targeting FOXK1 and BCL-2/AKT Signaling in Gastric Cancer
- (2017) Pei Zhang et al. GASTROENTEROLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
- (2017) Floriana Morgillo et al. Oncotarget
- Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
- (2017) Masayuki Yamaji et al. Cancer Medicine
- PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
- (2016) J.S. de Bono et al. ANNALS OF ONCOLOGY
- Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway
- (2016) D. Mo et al. CANCER RESEARCH
- A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses
- (2016) Eric H. Bent et al. GENES & DEVELOPMENT
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Targeting tumor suppressor genes for cancer therapy
- (2015) Yunhua Liu et al. BIOESSAYS
- Disruption of Zebrafish Follicle-Stimulating Hormone Receptor (fshr) But Not Luteinizing Hormone Receptor (lhcgr) Gene by TALEN Leads to Failed Follicle Activation in Females Followed by Sexual Reversal to Males
- (2015) Zhiwei Zhang et al. ENDOCRINOLOGY
- Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer
- (2015) Chandan Rana et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
- (2014) D. Chen et al. CLINICAL CANCER RESEARCH
- Aurora Kinase Inhibition Induces PUMA via NF- B to Kill Colon Cancer Cells
- (2014) J. Sun et al. MOLECULAR CANCER THERAPEUTICS
- Celastrol Induces Apoptosis of Gastric Cancer Cells by miR-21 Inhibiting PI3K/Akt-NF-κB Signaling Pathway
- (2014) Min Sha et al. PHARMACOLOGY
- FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
- (2013) E. E. Santo et al. CANCER RESEARCH
- Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
- (2013) Y. Yan et al. CLINICAL CANCER RESEARCH
- Colorectal cancer
- (2013) Hermann Brenner et al. LANCET
- Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies
- (2012) Heidi M. Savage et al. CANCER RESEARCH
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
- (2011) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway
- (2011) S. R. Boreddy et al. CLINICAL CANCER RESEARCH
- Unknown
- (2011) Zhu Yuan et al. MOLECULAR MEDICINE
- Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , PI3K and Akt1
- (2010) Martha L. Slattery et al. CARCINOGENESIS
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
- (2009) M. G. Kharas et al. BLOOD
- PUMA is directly activated by NF-κB and contributes to TNF-α-induced apoptosis
- (2009) P Wang et al. CELL DEATH AND DIFFERENTIATION
- PUMA Promotes Bax Translocation by Both Directly Interacting with Bax and by Competitive Binding to Bcl-XL during UV-induced Apoptosis
- (2009) Yingjie Zhang et al. MOLECULAR BIOLOGY OF THE CELL
- PUMA, a potent killer with or without p53
- (2009) J Yu et al. ONCOGENE
- 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways
- (2009) C Guo et al. ONCOGENE
- Deregulation of the Akt Pathway in Human Cancer
- (2008) Eriko Tokunaga et al. CURRENT CANCER DRUG TARGETS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started